Phibro Animal Health (NASDAQ:PAHC) Stock Crosses Above 50 Day Moving Average - Here's What Happened

Key Points

• Phibro Animal Health's stock crossed above its 50-day moving average of $36.78, trading as high as $40.15, with a last traded price of $39.72.
• Several analysts have recently upgraded their ratings on the stock, including Zacks Research, which moved its rating from "hold" to "strong-buy."
• The company reported better-than-expected quarterly earnings with an EPS of $0.57, surpassing the consensus estimate of $0.52, alongside a revenue of $378.70 million.

Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) shares passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $36.78 and traded as high as $40.15. Phibro Animal Health shares last traded at $39.72, with a volume of 196,726 shares trading hands.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Weiss Ratings restated a "hold (c)" rating on shares of Phibro Animal Health in a research note on Tuesday. Zacks Research upgraded shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research note on Monday, September 29th. Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a research note on Thursday, August 28th. Bank of America raised their target price on shares of Phibro Animal Health from $19.00 to $27.00 and gave the company an "underperform" rating in a research note on Friday, August 29th. Finally, JPMorgan Chase & Co. upgraded shares of Phibro Animal Health from a "neutral" rating to an "overweight" rating and raised their target price for the company from $25.00 to $35.00 in a research note on Monday, July 7th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, four have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.40.

Phibro Animal Health Stock Up 3.0%

The company's 50 day moving average price is $36.78 and its 200 day moving average price is $28.32. The company has a quick ratio of 1.25, a current ratio of 2.76 and a debt-to-equity ratio of 2.46. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 1.16 and a beta of 0.83.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, August 27th. The company reported $0.57 EPS for the quarter, topping the consensus estimate of $0.52 by $0.05. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. The business had revenue of $378.70 million during the quarter, compared to the consensus estimate of $362.24 million. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. As a group, research analysts forecast that Phibro Animal Health Corporation will post 1.95 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were issued a dividend of $0.12 per share. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. The ex-dividend date of this dividend was Wednesday, September 3rd. Phibro Animal Health's dividend payout ratio (DPR) is 40.68%.

Insider Activity

In related news, CEO Jack Bendheim sold 14,080 shares of the firm's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $40.33, for a total transaction of $567,846.40. Following the completion of the transaction, the chief executive officer owned 45,400 shares of the company's stock, valued at $1,830,982. This trade represents a 23.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 24,622 shares of company stock worth $995,893 over the last three months. Company insiders own 50.13% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in PAHC. Principal Financial Group Inc. raised its holdings in shares of Phibro Animal Health by 2.6% during the first quarter. Principal Financial Group Inc. now owns 101,356 shares of the company's stock worth $2,165,000 after purchasing an additional 2,573 shares during the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in shares of Phibro Animal Health during the first quarter worth $1,411,000. Hussman Strategic Advisors Inc. raised its holdings in shares of Phibro Animal Health by 20.0% during the first quarter. Hussman Strategic Advisors Inc. now owns 126,000 shares of the company's stock worth $2,691,000 after purchasing an additional 21,000 shares during the last quarter. Csenge Advisory Group raised its holdings in shares of Phibro Animal Health by 26.4% during the first quarter. Csenge Advisory Group now owns 26,143 shares of the company's stock worth $558,000 after purchasing an additional 5,456 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in shares of Phibro Animal Health during the first quarter worth $331,000. Hedge funds and other institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.